Johnson & Johnson $JNJ Holdings Boosted by Candriam S.C.A.

Key Points

• Candriam S.C.A. increased its Johnson & Johnson stake by 1.3% in the third quarter, adding 6,468 shares and bringing its holding to 516,642 shares, valued at about $137.3 million. Institutional investors and hedge funds collectively own 69.55% of J&J.
• J&J beat quarterly earnings expectations, reporting EPS of $2.59 versus $2.53 expected and revenue of $25.40 billion, up 5.9% year over year. The company forecast fiscal 2026 EPS of $11.05–$11.15.
• Analysts have a Moderate Buy consensus rating and an average price target of $275.92; J&J also announced a quarterly dividend of $1.34 per share, equivalent to a 1.9% yield.

Candriam S.C.A. raised its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.3% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 516,642 shares of the company's stock after acquiring an additional 6,468 shares during the period. Candriam S.C.A.'s holdings in Johnson & Johnson were worth $137,276,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in JNJ. American State Bank Iowa increased its stake in shares of Johnson & Johnson by 2.4% during the third quarter. American State Bank Iowa now owns 13,843 shares of the company's stock worth $3,665,000 after acquiring an additional 324 shares during the period. Cooper Haims Advisors LLC lifted its position in Johnson & Johnson by 11.8% in the third quarter. Cooper Haims Advisors LLC now owns 2,187 shares of the company's stock valued at $579,000 after purchasing an additional 231 shares during the period. J. Derek Lewis & Associates Inc. lifted its position in Johnson & Johnson by 10.0% in the third quarter. J. Derek Lewis & Associates Inc. now owns 2,926 shares of the company's stock valued at $774,000 after purchasing an additional 265 shares during the period. Ethic Inc. boosted its holdings in Johnson & Johnson by 20.3% in the 3rd quarter. Ethic Inc. now owns 132,061 shares of the company's stock valued at $34,962,000 after purchasing an additional 22,303 shares in the last quarter. Finally, 180 Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 88.6% in the 3rd quarter. 180 Wealth Advisors LLC now owns 24,052 shares of the company's stock valued at $6,367,000 after purchasing an additional 11,301 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

JNJ has been the topic of several recent analyst reports. Argus set a $300.00 target price on Johnson & Johnson in a research report on Wednesday, July 29th. TD Cowen reaffirmed a "buy" rating on shares of Johnson & Johnson in a report on Tuesday, October 20th. Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a report on Thursday, October 15th. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $282.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.92.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $276.14 on Monday. Johnson & Johnson has a 12-month low of $185.12 and a 12-month high of $282.02. The stock has a market cap of $664.76 billion, a P/E ratio of 41.84, a PEG ratio of 2.73 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $265.91 and a two-hundred day moving average of $248.30.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same period in the prior year, the business earned $2.80 earnings per share. The company's quarterly revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is 81.21%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.